CAIX is a predictor of pathological complete response and is associated with higher survival in locally advanced breast cancer submitted to neoadjuvant chemotherapy

BACKGROUND: Locally advanced breast cancer often undergoes neoadjuvant chemotherapy (NAC), which allows in vivo evaluation of the therapeutic response. The determination of the pathological complete response (pCR) is one way to evaluate the response to neoadjuvant chemotherapy. However, the rate of...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:BMC Cancer
Auteurs principaux: Alves, Wilson Eduardo Furlan Matos, Bonatelli, Murilo, Dufloth, Rozany, Kerr, Lígia Maria, Carrara, Guilherme Freire Angotti, da Costa, Ricardo Filipe Alves, Scapulatempo-Neto, Cristovam, Tiezzi, Daniel, da Costa Vieira, René Aloísio, Pinheiro, Céline
Format: Artigo
Langue:Inglês
Publié: BioMed Central 2019
Sujets:
Research Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6889185/
https://ncbi.nlm.nih.gov/pubmed/31795962
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-019-6353-2
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires